MedTrace Logo

Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer

NCT03132025 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-04-27

No results posted yet for this study

Summary

To control apatinib and capecitabine combination to maintain treating metastatic colorectal cancer.

Conditions

Interventions

DRUG

"Apatinib" and "Capecitabine"

Combine "Apatinib" and "Capecitabine" to Maintain Treating Metastatic Colorectal Cancer

DRUG

"Capecitabine"

Single Drug "Capecitabine" to Maintain Treating Metastatic Colorectal Cancer

Sponsors & Collaborators

  • Yanqiao Zhang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-30
Primary Completion
2018-02-28
Completion
2018-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03132025 on ClinicalTrials.gov